Gliclazid

Sulphonylureas Chlorpropamide, glibenclamideb, gliclazide, glimepiride, glipizide, gliquidone, tolazamide, tolbutamide Stimulate insulin secretion (typically 6-24 h) Oral... 

Several studies have demonstrated that treatment of diabetic patients with the sulphonylurea, gliclazide, is associated with a fall in lipid peroxidation, protein fluorescence and beneficial effects on platelet function (Florkowski et al., 1988 Jennings et al., 1992). These changes were seen to be independent of changes in giycaemic control. 

Rosiglitazone is a thiazolidinedione that can be used in combination with metformin or a sulphonylurea such as gliclazide. Rosiglitazone should be administered with caution in patients with cardiovascular disease. 

Gliclazide is a sulphonylurea. In general, diabetic patients are switched over to insulin during pregnancy. Sulphonylureas should be stopped at least 2 days... 

Gliclazide is slowly absorbed. It is metabolized and excreted in the urine, in part as unchanged drug with an elimination half-life of 6-14 hours. Its duration of action is about 12 hours. Glicazide reduces platelet adhesiveness and increases fibrinolytic activity. This could be of importance as both factors have been implicated in the pathogenesis of the longterm organ failure in diabetes. 

However additional peculiarities are found in some preparations. Glimepiride results in lower insulin and C-peptide levels with similar glucose control, probably due its greater extrapancreatic effect on insulin target tissues. Gliclazide has a lower secondary failure rate than glyburide or glipizide. 

Gliclazide reduces blood glucose levels by correcting both defective insulin secretion and peripheral insulin resistance. 

Gliclazide also has been reported to reduce plasma cholesterol and triglyceride levels after repeated administration. 

---